Broker snap: UBS upgrades Hikma after recent falls
17th Apr 2012 10:47
UBS has upgraded its rating for pharmaceuticals group Hikma from neutral to buy, leaving its 755p target price unchanged, following the sell-off since the firm's full-year results last month. The broker sees a 10% and 6% downside risk to 2012 and 2013 earnings per share estimates - "we believe cons
Read moreTuesday broker round-up - UPDATE
17th Apr 2012 08:36
BHP Billiton: Jefferies reiterates buy rating and 2,500p target. Burberry: Merchant Securities downgrades from buy to hold; Investec maintains buy recommendation and 1,690p target. Dairy Crest: Numis upgrades from add to buy. Daily Mail & General Trust: Investec maintains buy rating and 578p targ
Read moreFriday broker round-up - UPDATE
16th Mar 2012 10:27
4imprint: Peel Hunt keeps buy rating and 345p target. Aegis: Nomura reiterates buy rating and 210p target; HB Markets upgrades from sell to hold. Antofagasta: Jefferies keeps hold and 1,214p target. Bunzl: Goldman Sachs downgrades from neutral to sell, target lifted from 940p to 988p. Diageo: Je
Read moreExceptional charges dent Hikma's profits
14th Mar 2012 08:09
Drugs developer Hikma Pharmaceuticals kept up its track record of doubling revenues every four years, but it will be less pleased with the slide in profits in 2011 as exceptional charges increased. Profits before tax fell from $120.98m to $93.89m, after operating expenses soared. Group operating ex
Read moreMonday broker round-up - UPDATE
14th Nov 2011 09:19
Barclays: Goldman Sachs cuts to sell from neutral. BG Group: Evolution Securities keeps buy recommendation and 1,800p target. BG Group: Nomura maintains buy and 1,750p target. ITV: Peel Hunt retains buy and 73p target. ITV: Investec maintains hold rating and 55p target. Cairn Energy: UBS cuts
Read moreHikma non execs buy big stakes
18th Oct 2011 15:34
Two non-executive directors at Hikma Pharmaceuticals have upped their stakes in the Arab world-focused pharmaceutical company. Ronald Goode took 8,000 shares at 633p a time, lifting his stake to 22,700 shares, while Robert Pickering snapped up 7,500 shares at 617p a pop, having previously had none.
Read moreWednesday tips round-up: Carillion, Hamworthy, Heritage Oil...
5th Oct 2011 06:57
Carillion, which bought Eaga, the home insulation and green energy business, in the spring, has now raised its estimate for annualised cost savings from £9 million to £15 million, notes the Tempus column in the Times. Carillion, like its rival support services group Kier, is now seeing the promised,
Read moreBroker tips: Tullow Oil, IG Group, Hikma
26th Aug 2011 12:48
UBS says that Tullow Oil is in a comfortable financial position, and with catalysts "plentiful" in September, the broker keeps its buy rating on the Africa-focused oil giant. "With the expectation of receiving $2.9bn cash for the sale of its Ugandan assets, coupled with growing cashflows from Jubil
Read moreBroker snap: UBS cuts target for Hikma after first half miss
26th Aug 2011 12:47
UBS has cut its target price for FTSE 250 pharmaceuticals firm Hikma from 900p to 850p after first half revenues and earnings came in below forecasts. The broker notes that revenues in the six months to 30 June of $395m missed its forecasts by 1.7% and consensus estimates by 0.4%. "While reported
Read moreLibyan civil war hurts Hikma
25th Aug 2011 10:27
Disruption in Libya and Yemen contributed to a fall in profits at pharmaceuticals group Hikma in the half year to 30 June. Gross profit fell to $172.6m from $178.5m over the same period the previous year, on revenues that climbed to $394.8m from $377.7m. Gross profits in the company's branded prod
Read moreHikma to distribute iron deficiency treatment
17th Aug 2011 07:09
Drugs developer Hikma Pharmaceuticals is to market Ferinject, Vifor Pharma's treatment for iron deficiency, in the Middle East and North African (MENA) region. The agreement covers Algeria, Egypt, Iraq, Jordan, Lebanon, Libya, Morocco, South Sudan, Sudan, Syria, Tunisia and Yemen; collectively, the
Read moreHikma acquires minority stake in Chinese pharma company
11th Jul 2011 10:42
Generic drugs maker Hikma Pharmaceuticals has acquired a minority stake in China's Hubei Haosun Pharmaceutical through the subscription of new equity for $5m in cash. This deal will give Hikma access to the Chinese company's Wuhan province facility, which is certified by the U.S. Food and Drug Admi
Read moreIAG non-exec opens account with £2.5m purchase
26th May 2011 16:13
Non-executive chairman Cesar Alierta Izuel has opened his account in British Airways owner International Consolidated Airlines in a big way, spending nearly £2.5m on shares. He took 165,000 shares at €2.82 a time, 729,575 at €2.84 and 105,425 at €2.75. Izuel has been on the board of IAG since the
Read moreLondon close: Late rally falls short
12th May 2011 16:58
Shares clawed back some of their losses ahead of the close but still finished firmly in the red as miners sank in line with commodity prices. Metals prices were on the decline amid monetary tightening in China, hurting mining stocks such as Fresnillo, Vedanta Resrouces and Kazakhmys. Lower oil pric
Read moreSector movers: Miners fall on commodities sell-off
12th May 2011 15:16
Unsurprisingly, the miners are the worst performing stocks on Thursday, as commodity prices continue to decline. Fresnillo, Antofagasta, Vedanta Resources, Kazakhmys and Lonmin are among the fallers on the FTSE 100. Eurasian Natural Resources Corporation is lower even though it reported a positive
Read more